Taurohyodeoxycholic acid-d4 (sodium)

Taurohyodeoxycholic acid-d4 (sodium)

• UNSPSC Description: Taurohyodeoxycholic acid-d4 (sodium) is a deuterated labeled Taurohyodeoxycholic acid (sodium)[1]. Taurohyodeoxycholic acid (THDCA) sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. Taurohyodeoxycholic acid can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model.
• Target Antigen: Interleukin Related; Isotope-Labeled Compounds; TNF Receptor
• Type: Isotope-Labeled Compounds
• Related Pathways: Apoptosis;Immunology/Inflammation;Others
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/taurohyodeoxycholic-acid-d4-sodium.html
• Smiles: C[C@@]12[C@]3([H])[C@](C[C@@H]([C@]1([H])C[C@@H](CC2)O)O)([H])[C@@]4([H])[C@](CC3)([C@@](CC4)([H])[C@H](C)CCC(NC([2H])([2H])C([2H])([2H])S(=O)(O)=O)=O)C.[Na].[x]
• Molecular Weight: 499.70 (free acid)
• References & Citations: [1]Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27(2):520-5. |[2]Angelico M, et al. Dissolution of human cholesterol gallstones in bile salt/lecithin mixtures: effect of bile salt hydrophobicity and various pHs. Scand J Gastroenterol. 1995 Dec;30(12):1178-85. |[3]Angelico M, et al. Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. Dig Dis Sci. 1994 Nov;39(11):2389-97. |[4]Solmon Kusuma S, et al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma[J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2014, 14(9): 1237-1248. |[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
• Shipping Conditions: Room temperature
• Clinical Information: Phase 4